![Monica Bertagnolli: Fascinating research I recently read about CAR-T therapy](https://oncodaily.com/pub/uploads/2024/05/Screenshot-2024-05-12-at-22.39.05-1280x544.png)
Monica Bertagnolli: Fascinating research I recently read about CAR-T therapy
Monica Bertagnolli shared a post on LinkedIn:
”Fascinating research I recently read about in the New England Journal of Medicine. A team of scientists from FAU Erlangen-Nürnberg used CAR-T therapy, a method of engineering immune cells to fight cancer, as a treatment method for 15 patients with various autoimmune diseases. In the study’s follow-up period, all patients reported not needing to use the medications typically used to manage their conditions. While this is an early, small study – I am excited by the promise of these findings and what it could mean for patients with autoimmune conditions.”
Source: Monica Bertagnolli/LinkedIn
Monica Bertagnolli is the Director of the National Institute of Health (NIH), USA. She previously served as the Richard E. Wilson Professor of Surgery in the field of surgical oncology at Harvard Medical School, a surgeon at Brigham and Women’s Hospital, and a member of the Gastrointestinal Cancer Treatment and Sarcoma Centers at Dana-Farber Cancer Institute. Dr. Bertagnolli is the Founding Chair of the minimal Common Oncology Data Elements (mCODE) executive committee and has held multiple positions nationally, including being Past President and Chair of the Board of Directors of the American Society of Clinical Oncology, Chair of the Alliance for Clinical Trials in Oncology. In 2021, she was elected to the National Academy of Medicine, having previously served on the National Academies National Cancer Policy Forum.